Founded Year

2017

Stage

Series B | Alive

Total Raised

$21.71M

Last Raised

$16.76M | 6 mos ago

About Pin Therapeutics

Pin Therapeutics is a pharmaceutical company that creates therapeutic products based on chemical biology-driven protein degradation, including PROTAC technology. The company aims to develop PROTAC compounds for oncology, neurodegenerative diseases, and cardiovascular indications based on disease-agnostic approaches.

Pin Therapeutics Headquarter Location

329 Oyster Point Blvd 3rd Floor

South San Francisco, California, 94080,

United States

070-8693-3497

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Pin Therapeutics's Products & Differentiation

See Pin Therapeutics's products and how their products differentiate from alternatives and competitors

  • CK1a-selective molecular glue degrader

    A drug for acute myeloid leukemia treatment. It works as degrading CK1a, an important protein for cancer prognosis. It is a molecular glue degrader (monovalent chemical structure)

    Differentiation

    New treatment option for AML, first-in-class drug, novel selective molecular glue degrader (competitors' are not degraders and they are not selective inhibitors) 

  • Subscribe to see more

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

    Differentiation

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

  • Subscribe to see more

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

    Differentiation

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

Expert Collections containing Pin Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Pin Therapeutics is included in 2 Expert Collections, including Biopharma Tech.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

  • When was Pin Therapeutics founded?

    Pin Therapeutics was founded in 2017.

  • Where is Pin Therapeutics's headquarters?

    Pin Therapeutics's headquarters is located at 329 Oyster Point Blvd, South San Francisco.

  • What is Pin Therapeutics's latest funding round?

    Pin Therapeutics's latest funding round is Series B.

  • How much did Pin Therapeutics raise?

    Pin Therapeutics raised a total of $21.71M.

  • Who are the investors of Pin Therapeutics?

    Investors of Pin Therapeutics include KB Investment, WE ventures, Company K Partners, Korea Investment Partners, Korea Investment & Securities and 11 more.

  • Who are Pin Therapeutics's competitors?

    Competitors of Pin Therapeutics include C4 Therapeutics and 3 more.

  • What products does Pin Therapeutics offer?

    Pin Therapeutics's products include CK1a-selective molecular glue degrader and 2 more.

You May Also Like

F
FIMECS

FIMECS is a drug discovery biotech firm focused on developing protein degradation therapeutics for cancers and other difficult-to-treat diseases.

Arvinas Logo
Arvinas

Arvinas (NASDAQ: ARVN) is a pharmaceutical company focused on developing small molecules aimed at degrading disease-causing cellular proteins. The company is translating these protein degradation approaches into drugs for the treatment of cancer and other diseases. Many diseases are a result of "rogue," uncontrolled proteins, whose absence could bring great clinical benefit to patients.

Kymera Therapeutics Logo
Kymera Therapeutics

Kymera Therapeutics (NASDAQ: KYMR) is a biotechnology company that develops an approach to treating previously untreatable diseases. Kymera aims to accelerate drug discovery with an ability to target and degrade proteins and advance treatment options for patients.

Nurix Therapeutics Logo
Nurix Therapeutics

Nurix Therapeutics discovers drugs that harness the body's natural process to control protein levels. The drugs control ubiquitin E3 ligases, the key enzymes responsible for protein breakdown in human cells, as a unique therapeutic approach to treat a broad range of diseases.

C4 Therapeutics Logo
C4 Therapeutics

C4 Therapeutics (NASDAQ: CCCC) advances a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of cells.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.